Drug Profile

PD-1 knockout T cell therapy - CELLBIOTECH

Latest Information Update: 17 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CELLBIOTECH
Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
Mechanism of Action Gene transference; Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

17 Sep 2023 Discontinued - Preclinical for Solid tumours in South Korea (Parenteral)
28 Sep 2020 No recent reports of development identified for preclinical development in Solid-tumours in South Korea (Parenteral, Infusion)
12 Aug 2016 Cell Biotech and Peking University plan a phase I trial for Prostate cancer (Hormone refractory) in China (Parenteral) (NCT02867345)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com